Repertoire initiates trial of T cell-targeted immune medicine
Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours. The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational… Read More